Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zenas BioPharma (ZBIO) Equity Ratio (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Equity Ratio data on record, last reported at 0.61 in Q3 2025.

  • For Q3 2025, Equity Ratio fell 31.53% year-over-year to 0.61; the TTM value through Sep 2025 reached 0.61, down 31.53%, while the annual FY2024 figure was 0.84, 125.51% up from the prior year.
  • Equity Ratio reached 0.61 in Q3 2025 per ZBIO's latest filing, down from 0.82 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.89 in Q3 2024 and bottomed at 3.31 in Q4 2023.
  • Average Equity Ratio over 3 years is 0.12, with a median of 0.83 recorded in 2025.
  • Peak YoY movement for Equity Ratio: soared 125.51% in 2024, then tumbled 31.53% in 2025.
  • A 3-year view of Equity Ratio shows it stood at 3.31 in 2023, then skyrocketed by 125.51% to 0.84 in 2024, then dropped by 27.77% to 0.61 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.61 in Q3 2025, 0.82 in Q2 2025, and 0.85 in Q1 2025.